Successful clinical application of CRISPR/Cas9 for genetic disorders, such as sickle cell disease and β-thalassemia, validated the therapeutic strategy for genome editing and paved the way for targeting cancer and hereditary diseases associated with mutated or impaired TP53 gene. This evidence concerns the gene TP53 and cancer.